GlassScriptPhysician profile
Gerardo Rivera
NPI 1992399125
$6,541.45
in general payments reported to CMS, 2019-2025
28 companies · $778 in 2025
The $778 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $717 · 2022: $1,806 · 2023: $2,027 · 2024: $1,213 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,017.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,492.58 | 2021-2024 | |
| Amgen INC. | $1,085.25 | 2021-2024 | Enbrel, Tavneos, Evenity |
| Astrazeneca Pharmaceuticals LP | $752.06 | 2021-2025 | Saphnelo, Flumist Quadrivalent |
| Lilly USA, LLC | $354.30 | 2022-2024 | Taltz, Mounjaro |
| Janssen Biotech, INC. | $345.61 | 2023-2025 | Tremfya, Simponi Aria, Erleada |
| Ucb, INC. | $335.74 | 2023-2024 | Cimzia |
| Novo Nordisk INC | $328.35 | 2022-2024 | |
| Madrigal Pharmaceuticals | $254.41 | 2025 | Rezdiffra |
| Viiv Healthcare Company | $235.35 | 2025 | Apretude |
| Pfizer INC. | $230.02 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $219.40 | 2023-2025 | |
| Glaxosmithkline, LLC. | $140.69 | 2022-2024 | Benlysta |
| Ani Pharmaceuticals, INC. | $140.06 | 2023-2024 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $121.82 | 2025 | Yeztugo |
| Kiniksa Pharmaceuticals, LTD. | $101.38 | 2023 | Arcalyst |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $61.39 | 2023-2024 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $53.51 | 2021-2023 | Strensiq |
| Mallinckrodt Hospital Products INC. | $52.27 | 2023-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.37 | 2023 | Cyltezo |
| Sobi, INC | $30.63 | 2023 | |
| Ferring Pharmaceuticals INC. | $27.48 | 2025 | Adstiladrin |
| Mylan Institutional INC. | $26.18 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $22.50 | 2024 | Orencia |
| Shionogi INC | $21.90 | 2022 | |
| Exelixis INC. | $20.84 | 2025 | Cabometyx |
| Kiniksa Pharmaceuticals International, Plc | $19.59 | 2024 | Arcalyst |
| Biocon Biologics INC | $18.91 | 2023 | Hulio |
| Kyowa Kirin, INC. | $17.86 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.